 Shares of Five Prime Therapeutics skyrocketed early Wednesday after the tiny biotech stocks stomach cancer treatment, a drug known as bemarituzumab, passed muster in a midstage test. The post Why This Tiny Biotech Stock Just Skyrocketed 285 In Bullish Volume appeared first on Investors Business Daily. 